| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2005;46:227.)
© 2005 American Heart Association, Inc.
Fifth International Workshop on Structure and Function of Large Arteries |
From the Department of Cardiology (M.S., J.R.C.), Wales Heart Research Institute, College of Medicine University Hospital of Wales, Cardiff, UK; Graduate School of Biomedical Engineering (A.A., A.Q., M.B.), University of New South Wales, Sydney, Australia; and Clinical Pharmacology Unit (C.M.M., I.B.W.), University of Cambridge, Addenbrookes Hospital, United Kingdom.
Correspondence to Professor John Cockcroft, Department of Cardiology, Wales Heart Research Institute, College of Medicine University Hospital of Wales, Cardiff, UK. E-mail cockcroftjr{at}cf.ac.uk
| Abstract |
|---|
|
|
|---|
Key Words: arteries nitric oxide arterial stiffness hemodynamics
| Introduction |
|---|
|
|
|---|
The aim of the present study was to test the hypothesis that NO is important in regulating large artery stiffness in man using local infusions of drugs to modulate the L-arginine NO pathway, thus avoiding the confounding effects of changes in MAP. The methodology was adapted form that used previously in the ovine iliac artery.7
| Methods |
|---|
|
|
|---|
30% lumen diameter. The demographic data, cardiovascular risk profile, and medication before angiography are outlined in Table 1. All subjects gave written informed consent. The protocol was approved by the Local Research Ethics Committee and conducted in accordance with local regulations.
|
Hemodynamic Measurements
Intravascular pressure measurements were made using custom-made Millar Mikro-Tip 6F end-hole catheters with a 0.46-mm internal lumen, and dual high-fidelity pressure sensors located 10 and 60 mm from the distal end. The analogue signal from the pressure control unit (Millar TC-510) was interfaced with an analogue-to-digital converter (Biopac Systems) and fed into a portable microcomputer, with a sampling rate of 1 kHz. Data were recorded over
20 s to allow for variations within the respiratory cycle and then exported and resampled at 10 kHz for further analysis with custom-written MATLAB analysis program (Mathworks). Using this program, systolic diastolic, and pulse pressure and MAP were determined together with the transit time between the 2 pressure waveforms, from the distal sensor, as described previously.7 The minimum resolution of the system was a difference of 0.1 ms. The iliac PWV was calculated from the transit time, as illustrated in Figure 1, and the fixed distance between the recording sites (50 mm). The PWV is inversely related to arterial distensibility by the equation of Bramwell and Hill13; PWV=
[V ·
P/
·
V], where: V=artery volume,
V=change in volume,
P=change in pressure, and
=blood density (assumed to be constant during the study). Heart rate (HR) was recorded simultaneously via a 3-lead ECG. Brachial MAP was assessed at baseline and immediately after each infusion period by oscillometric sphygmomanometer (Dinamap Critikon).
|
Drugs
All drugs were freshly prepared in an aseptic manner using 0.9% saline as a diluent. Glyceryl trinitrate (GTN; Schwarz) was infused at 4 nmol/min and L-NMMA (Clinalfa) at 8 and 16 µmol/min. All infusions were at 1 mL/min for 5 minutes.
Protocol
All subjects were studied after diagnostic angiography and while resting supine in a temperature-controlled environment. Vasoactive drugs were omitted on the day of the study. The arterial catheter was positioned in the right common iliac artery under radiographic screening, with the tip well below the level of the aortic bifurcation, and most distal sensor at least 5 cm from the sheath (Figure 2). Iliac angiography was performed to rule out presence of iliac artery disease and to select a segment without branching (Figure 3). Saline was then infused for 15 minutes to maintain patency and to allow stabilization of the preparation. Baseline measurements of iliac PWV, iliac blood pressure, and HR were recorded in duplicate. In 6 patients, GTN was infused at 4 nmol/min, first through the sheath and then through the catheter. In another 12 patients, L-NMMA was then infused at 16 µmol/min first through the sheath, and then at 8 µmol/min and 16 µmol/min through the catheter. Infusion of L-NMMA through the catheter exposed the arterial segment under study to the drug, whereas infusion via the sheath did not because the drug is delivered distal to the pressure sensors (Figure 2). Pressure waveforms were recorded during the final 20 s of each infusion.
|
|
Statistical Analysis
All results are expressed as means±SEM. Data were analyzed by 2-way ANOVA with post hoc comparison to baseline. Pair-wise Spearman rank analysis was performed to assess correlations between iliac MAP and PWV. A P value <0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
Infusion of L-NMMA
Hemodynamic data are presented in Table 2. There was no significant change in brachial or iliac MAP throughout the study. Iliac pulse pressure did not alter after infusion of L-NMMA via the sheath but increased significantly after catheter infusion. However, there was no significant difference between sheath and catheter responses. Compared with the control infusion via the sheath, there was a significant fall of 3 bpm in HR when L-NMMA was infused via the catheter.
|
There was small, nonsignificant increase in the iliac PWV after infusion of L-NMMA via the sheath (0.88±0.19 m/s; P=NS). Infusion of L-NMMA via the catheter led to a significant, dose-dependent increase in PWV (0.94±0.20, and 2.61±0.19 m/s, respectively; P=0.001). The increase in PWV remained significant when infusion of equimolar dose through the catheter and sheath were compared (P<0.02; Figure 4). There was no correlation between the change in iliac PWV and the change in MAP or HR.
|
| Discussion |
|---|
|
|
|---|
Using pulse wave analysis and systemic infusion of L-NMMA, we demonstrated previously that NO plays a role in regulation of large artery distensibility.25 However, results of this study were difficult to interpret because of changes in systemic blood pressure that would have influenced distensibility. Local infusion of drugs, such as L-NMMA, avoids such confounding factors. Indeed, using such an approach, we demonstrated previously in an ovine hindlimb model that NO, in part, regulates iliac artery distensibility independently of alterations in MAP or HR.7 We recently extended these studies to demonstrate that nebivolol, a ß-blocker that releases NO, also decreases iliac artery distensibility independently of any reduction in blood pressure.26 The aim of the present study was to use this methodology to test the hypothesis that NO regulates large artery distensibility in man. The main findings were that inhibition of basal NO production increased the PWV, and that infusion of the NO donor GTN decreased PWV. Both these effects were independent of changes in MAP or HR. Interestingly, iliac pulse pressure increased after infusion of L-NMMA, in keeping with an increase in local artery stiffness. Together, these data indicate that NO regulates local iliac artery distensibility in man.
Previous data concerning the role of endogenous NO in modulating large artery distensibility in humans are controversial, not least because of differences in experimental techniques but also the vessels studied.1012,27 Indeed, the majority of human studies have been performed in the arm.10,11,27 Although the radial and brachial arteries are easily accessible, they may not be the ideal vascular bed in which to study the involvement of basal NO in the physiological regulation of arterial distensibility. Indeed, unlike the aorta and large arteries of the lower extremities, clinically significant atherosclerosis in the arm vessels is an infrequent process. Intriguingly, brachial artery distensibility also changes little with age, unlike the aorta and femoral arteries, despite reduced brachial endothelial NO production with age.28,29 Moreover, the brachiocephalic system contributes little to the overall buffering capacity of the large arteries, unlike the aorto-femoral segment.6
Ramsey et al investigated the effects of NO on human iliac artery distensibility in health and chronic heart failure by infusing adenosine or the endothelium-dependent agonist acetylcholine (ACh).30 Whereas adenosine increased distensibility in controls and heart failure patients, changes in arterial distensibility after intra-arterial ACh were attenuated in chronic heart failure patients. However, they did not assess the contribution of basal NO to resting large artery distensibility. Moreover, ACh causes endothelial cells to release prostacyclin and endothelium-derived hyperpolarizing factor in addition to NO, and therefore, the role of NO, per se, in the observed changes is unclear. Therefore, in the present study, we used GTN as a specific NO donor and L-NMMA as an inhibitor of basal NO production and have provided firm evidence that NO modulates iliac distensibility in man. Interestingly, changes in the iliac artery were larger than those we reported previously in the ovine model,7 suggesting that inhibition of NO synthesis results in a similar degree of arterial stiffening as aging 20 years.28
Our results stand in contrast to those of Stewart et al,12 who examined the effects of systemic administration of L-NMMA on carotid-femoral PWV. In an attempt to control for the pressor effects of systemic NO synthase blockade, they also infused equipressor doses of noradrenaline and dobutamine and concluded that the increase in PWV produced by L-NMMA was solely explained by the changes in MAP. One obvious explanation for the differences between these 2 studies is the vessel studied. Stewart et al assessed carotid-femoral PWV, which includes the iliac and even more muscular femoral arteries. Differences in the techniques used may also be partly responsible because Stewart et al used surface estimation of PWV rather than intra-arterial determination, which may have limited their accuracy and thus the ability to resolve small differences between agents. Indeed, similar studies in animals using intra-arterial measurement of aortic PWV showed a greater increase in aortic PWV after NO synthase inhibition than after phenylephrine, a control constrictor.31 An alternative explanation is that norepinephrine and dobutamine had a direct effect on arterial smooth muscle or the endothelium, leading to direct stiffening of the artery as well as an increase in MAP in an analogous fashion to that produced by L-NMMA.
Limitations
The large arteries increase in muscularity moving away from the heart, becoming less "elastic."6 Therefore, the common iliac artery is more similar to the abdominal aorta than the ascending aorta. Nevertheless, the iliofemoral arterial segment still makes a significant contribution to cyclic pressure buffering6 and is routinely included in measurement of "aortic" PWV, when carotid and femoral sites are used for recording waveforms, as is the case with the SphygmoCor32 and Complior1 systems.
Patients undergoing diagnostic coronary angiography must not be considered "normal," even in absence of significant epicardial coronary artery disease and in absence of a (potentially false) positive stress test. With this in mind, and given the cardiovascular risk factors outlined in Table 1, it is likely that the findings of this study, if anything, quantitatively underestimate the true effect of basal NO on regulation of resting iliac artery distensibility in individuals without cardiovascular risk factors. Finally, there was a small but statistically significant change in HR after infusion of L-NMMA. It has been suggested that PWV33 and arterial distensibility34 may exhibit some dependence on HR. However, the magnitude of the change (a fall of 3 bpm) in the present study was small, and a fall in HR would be expected to reduce stiffness, leading us to underestimate the true NO effect.
Perspectives
Conventional cardiac risk factors, of which the majority not only impair endothelial function but also change the composition and thickness of the arterial wall, do not fully explain the incidence of coronary artery disease and cardiovascular events. Risk stratification and therapy based solely on these conventional risk factors will exclude a population who may benefit from lifestyle and risk factor modification. Arterial stiffening carries a number of serious adverse hemodynamic consequences, including a rise in pulse pressure, which tends to be more pronounced in the aorta than in the brachial artery because of wave reflection within the arterial tree.35 The resulting rise in aortic systolic pressure serves to increase left ventricular workload, promoting ventricular hypertrophy, itself a powerful predictor of cardiovascular mortality. It also increases the risk of coronary artery disease and stroke; whereas reduced diastolic pressure impairs coronary artery perfusion, predisposing to myocardial ischemia.36 Whatever the mechanism, arterial stiffening remains an important and independent predictor of cardiovascular risk, which will assume greater prominence because of the predicted growth in the older population of Western countries in future years. Here we show that endogenous NO locally modulates human iliac artery distensibility.
Assessment of arterial distensibility has the potential to identify patients at risk for later development of overt cardiovascular disease at an earlier stage than current clinically used techniques. Assessment of arterial distensibility, using various techniques, is likely to gain an important role in risk assessment and stratification. It may also be used for monitoring of therapeutic interventions, such as modulation of the NO pathway, especially in conditions associated with increased arterial stiffness.
| Acknowledgments |
|---|
Received February 11, 2005; first decision March 1, 2005; accepted March 22, 2005.
| References |
|---|
|
|
|---|
2. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, Ducimetiere P, Benetos A. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001; 37: 12361241.
3. Meaume S, Benetos A, Henry OF, Rudnichi A, Safar ME. Aortic pulse wave velocity predicts cardiovascular mortality in subjects >70 years of age. Arterioscler Thromb Vasc Biol. 2001; 21: 20462050.
4. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation. 2002; 106: 20852090.
5. Dobrin PB, Rovick AA. Influence of vascular smooth muscle on contractile mechanisms and elasticity of arteries. Am J Physiol. 1969; 217: 16441651.
6. Bergel DH. Cardiovascular Fluid Dynamics. London, UK: Academic Press; 1972.
7. Wilkinson IB, Qasem A, McEniery CM, Webb DJ, Avolio AP, Cockcroft JR. Nitric oxide regulates local arterial distensibility in vivo. Circulation. 2002; 105: 213217.
8. McEniery CM, Qasem A, Schmitt M, Avolio A, Cockcroft JR, Wilkinson IB. Endothelin-1 regulates arterial pulse wave velocity in vivo. J Am Coll Cardiol. 2003; 42: 19751981.
9. Schmitt M, Qasem A, McEniery C, Wilkinson IB, Tatarinoff V, Noble K, Klemes J, Payne N, Frenneaux MP, Cockcroft J, Avolio A. Role of natriuretic peptides in regulation of conduit artery distensibility. Am J Physiol. 2004; 287: H1167H1171.
10. Joannides R, Richard V, Haefeli WE, Benoist A, Linder L, Lusher TF, Thuillez C. Role of nitric oxide in the regulation of the mechanical properties of peripheral conduit arteries in humans. Hypertension. 1997; 30: 14651470.
11. Kinlay S, Creager MA, Fukumoto M, Hikita H, Fang JC, Selwyn AP, Ganz P. Endothelium-derived nitric oxide regulates arterial elasticity in human arteries in vivo. Hypertension. 2001; 38: 10491053.
12. Stewart AD, Millasseau SC, Kearney MT, Ritter JM, Chowienczyk PJ. Effects of inhibition of basal nitric oxide synthesis on carotid-femoral pulse wave velocity and augmentation index in humans. Hypertension. 2003; 42: 915918.
13. Bramwell JC, Hill AV. Velocity of transmission of the pulse-wave in man. Proc R Soc Lond B Biol Sci. 1922; 93: 298306.
14. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997; 349: 12691276.[CrossRef][Medline] [Order article via Infotrieve]
15. Vogel RA. Coronary risk factors, endothelial function, and atherosclerosis: a review. Clin Cardiol. 1997; 20: 426432.[Medline] [Order article via Infotrieve]
16. Luscher TF. The Endothelium in Cardiovascular Disease. New York, NY: Springer-Verlag; 1995.
17. Arnett DK, Evans GW, Riley WA. Arterial stiffness: a new cardiovascular risk factor. Am J Epidemiol. 1994; 140: 669682.
18. Glasser SP, Arnett DK, McVeigh GE, Finkelstein SM, Bank AJ, Morgan DJ, Cohn JN. Vascular compliance and cardiovascular disease: a risk factor or a marker? Am J Hypertens. 1997; 10: 11751189.[CrossRef][Medline] [Order article via Infotrieve]
19. Yasmin, McEniery CM, Wallace S, Mackenzie IS, Cockcroft JR, Wilkinson IB. C-reactive protein is associated with arterial stiffness in apparently healthy individuals. Arterioscler Thromb Vasc Biol. 2004; 24: 969974.
20. Vaitkevicius PV, Fleg JL, Engel JH, OConnor FC, Wright JG, Lakatta LE, Yin FC, Lakatta EG. Effects of age and aerobic capacity on arterial stiffness in healthy adults. Circulation. 1993; 88: 14561462.
21. Wilkinson IB, Cockcroft JR, Webb DJ. Pulse wave analysis and arterial stiffness. J Cardiovasc Pharmacol. 1999; 32: 3337.
22. Wilkinson IB, McEniery CM. Arterial stiffness, endothelial function and novel pharmacological approaches. Clin Exp Pharmacol Physiol. 2004; 31: 795799.[CrossRef][Medline] [Order article via Infotrieve]
23. Wilkinson IB, Franklin SS, Cockcroft JR. Nitric oxide and the regulation of large artery stiffness. From physiology to pharmacology. Hypertension. 2004; 44: 112116.
24. Ceravolo R, Maio R, Pujia A, Sciacqua A, Ventura G, Costa MC, Sesti G, Perticone F. Pulse pressure and endothelial dysfunction in never-treated hypertensive patients. J Am Coll Cardiol. 2003; 41: 17531758.
25. Wilkinson IB, MacCallum H, Cockcroft JR, Webb DJ. Inhibition of basal nitric oxide synthesis increases aortic augmentation index and pulse wave velocity in vivo. Br J Clin Pharmacol. 2002; 53: 189192.[CrossRef][Medline] [Order article via Infotrieve]
26. McEniery CM, Schmitt M, Qasem A, Webb DJ, Avolio AP, Wilkinson IB, Cockcroft JR. Nebivolol increases arterial distensibility in vivo. Hypertension. 2004; 44: 305310.
27. Leeson CMP, Whincup PH, Cook DG, Mullen MJ, Donald AE, Seymour CA, Deanfield JE. Cholesterol and arterial distensibility in the first decade of life: a population-based study. Circulation. 2000; 101: 15331538.
28. Avolio AP, Chen S-G, Wang R-P, Zahang C-L, Li M-F, ORourke MF. Effects of aging on changing arterial compliance and left ventricular load in a northern Chinese urban community. Circulation. 1983; 68: 5058.
29. Gerhard M, Roddy MA, Creager SJ, Creager MA. Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans. Hypertension. 1996; 27: 849853.
30. Ramsey MW, Goodfellow J, Jones CJH, Luddington LA, Lewis MJ, Henderson AH. Endothelial control of arterial distensibility is impaired in chronic heart failure. Circulation. 1995; 92: 32123219.
31. Fitch RM, Vergona R, Sullivan ME, Wang YX. Nitric oxide synthase inhibition increases aortic stiffness measured by pulse wave velocity in rats. Cardiovasc Res. 2001; 51: 351358.
32. Wilkinson IB, Fuchs SA, Jansen IM, Spratt JC, Murray GD, Cockcroft JR, Webb DJ. The reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. J Hypertens. 1998; 16: 20792084.[CrossRef][Medline] [Order article via Infotrieve]
33. Lantelme P, Mestre C, Lievre M, Gressard A, Milon H. Heart rate: an important confounder of pulse wave velocity assessment. Hypertension. 2002; 39: 10831087.
34. Mangoni AA, Mircoli L, Giannattasio C, Ferrari AU, Mancia G. Heart rate dependence of arterial distensibility in vivo. J Hypertens. 1996; 14: 897901.[CrossRef][Medline] [Order article via Infotrieve]
35. Nichols WW, ORourke MF. McDonalds Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles. 4th ed. London, UK: Arnold; 1998.
36. Franklin SS, Wong ND, Larson MG, Kannel WB, Levy D. How important is pulse pressure as a predictor of cardiovascular risk? Hypertension. 2002; 39: E12E13.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
D. A. Salzer, P. J. Medeiros, R. Craen, and J. K. Shoemaker Neurogenic-nitric oxide interactions affecting brachial artery mechanics in humans: roles of vessel distensibility vs. diameter Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2008; 295(4): R1181 - R1187. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Dhaun, J. Goddard, D. E. Kohan, D. M. Pollock, E. L. Schiffrin, and D. J. Webb Role of Endothelin-1 in Clinical Hypertension: 20 Years On Hypertension, September 1, 2008; 52(3): 452 - 459. [Full Text] [PDF] |
||||
![]() |
A. R. Malik, V. Kondragunta, and I. J. Kullo Forearm Vascular Reactivity and Arterial Stiffness in Asymptomatic Adults From the Community Hypertension, June 1, 2008; 51(6): 1512 - 1518. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Sharman, C. M. McEniery, R. Campbell, P. Pusalkar, I. B. Wilkinson, J. S. Coombes, and J. R. Cockcroft Nitric Oxide Does Not Significantly Contribute to Changes in Pulse Pressure Amplification During Light Aerobic Exercise Hypertension, April 1, 2008; 51(4): 856 - 861. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M.L. Wallace, Yasmin, C. M. McEniery, K. M. Maki-Petaja, A. D. Booth, J. R. Cockcroft, and I. B. Wilkinson Isolated Systolic Hypertension Is Characterized by Increased Aortic Stiffness and Endothelial Dysfunction Hypertension, July 1, 2007; 50(1): 228 - 233. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. McEniery, S. Wallace, I. S. Mackenzie, B. McDonnell, Yasmin, D. E. Newby, J. R. Cockcroft, and I. B. Wilkinson Endothelial Function Is Associated With Pulse Pressure, Pulse Wave Velocity, and Augmentation Index in Healthy Humans Hypertension, October 1, 2006; 48(4): 602 - 608. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Maki-Petaja, F. C. Hall, A. D. Booth, S. M.L. Wallace, Yasmin, P. W.P. Bearcroft, S. Harish, A. Furlong, C. M. McEniery, J. Brown, et al. Rheumatoid Arthritis Is Associated With Increased Aortic Pulse-Wave Velocity, Which Is Reduced by Anti-Tumor Necrosis Factor-{alpha} Therapy Circulation, September 12, 2006; 114(11): 1185 - 1192. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Dhaun, J. Goddard, and DavidJ. Webb The Endothelin System and Its Antagonism in Chronic Kidney Disease J. Am. Soc. Nephrol., April 1, 2006; 17(4): 943 - 955. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |